EDITOR'S NOTE

Time to Unveil the Risk of Imaging to Patients
D
espite the increased attention to the radiation risks of computed tomographic scans, this Research Letter by Caverly et al illustrates that most patients who are undergoing imaging tests are not aware of the associated risks of radiation exposure. It is likely that many physicians also do not know the risks, and so it is not surprising that even when there are discussions with patients about risks and benefits of the procedure, patients clearly still do not understand the true risk of radiation exposure. If we are to achieve optimal shared decision making on the decision to undergo imaging studies, much work needs to be done in educating physicians on the magnitude of radiation used for commonly used computed tomographic scans and the risks of radiation exposure so that we can unveil the true risk of imaging radiation exposure to our patients. This information, presented in a way that assures patient understanding of the risks, should be part of every discussion surrounding the decision to image. 2 and low-density lipoprotein cholesterol (LDL-C) levels (Ϫ9.2 mg/dL) 3 than usual care patients. The purpose of this Research Letter was to examine the economic and clinical benefits of GMC attendance 18 months following completion of the trial.
RESEARCH LETTERS
Benefits of Participation in Diabetes Group
Methods. Expenditure and utilization outcomes were obtained from Department of Veterans Affairs (VA) claims data, 4,5 and expenditures were inflation adjusted to 2010 dollars. Outpatient expenditures, total expenditures, and probability of inpatient admission during seven 6-month periods (2 prior to, 2 during, and 3 after the trial) were modeled using generalized estimating equations. These models included treatment arm, indicators for each 6-month period, and interactions of treatment and period for the five 6-month periods following intervention initiation.
Systolic BP, LDL-C, and HbA 1c measurements were ascertained from the VA electronic health record taken during any outpatient visit in the 42-month observation period. Unlike study-specific outcome values obtained at baseline, 6 months, and 12 months during the trial, each patient in this follow-up study had a varying number of clinic-based outcomes that were captured at different time intervals. There were natural transition points at baseline and trial conclusion, so piecewise quadratic mixedeffects models were fit with treatment by time interactions for differential trends by arm. These models had separate quadratic functions for the trial and posttrial periods, with time coded continuously as the number of weeks from baseline and centered at the points of discontinuity (baseline and trial conclusion). 6 The models for SBP and LDL-C included patient-level random effects for intercept and linear slope, quadratic time slope, and correlations between intercept and slopes. The model for HbA 1c included patient-level random effects for intercept and linear time and their correlation.
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